You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for DuP 697
DuP 697 is a potent and selective inhibitor of cyclooxygenase-2 (IC50 values are 10 and 800 nM for COX-2 and COX-1 respectively). Inhibits prostaglandin synthesis and is anti-inflammatory in vivo. Orally active.
Compound Libraries for DuP 697
Technical Data for DuP 697
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for DuP 697
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for DuP 697
The following data is based on the product molecular weight 411.3. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.43 mL||12.16 mL||24.31 mL|
|5 mM||0.49 mL||2.43 mL||4.86 mL|
|10 mM||0.24 mL||1.22 mL||2.43 mL|
|50 mM||0.05 mL||0.24 mL||0.49 mL|
References for DuP 697
References are publications that support the biological activity of the product.
Gans et al (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J.Pharmacol.Exp.Ther. 254 180 PMID: 2366180
Gierse et al (1995) Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem.J. 305 479 PMID: 7832763
Rossoni et al (2002) Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br.J.Pharmacol. 135 1540 PMID: 11906968
If you know of a relevant reference for DuP 697, please let us know.
View Related Products by Product Action
Keywords: DuP 697, DuP 697 supplier, Cyclooxygenase-2, COX-2, inhibitors, inhibits, Cyclooxygenase, Oxygenases, Oxidases, DuP697, 1430, Tocris Bioscience
5 Citations for DuP 697
Citations are publications that use Tocris products. Selected citations for DuP 697 include:
Choi et al (2010) Roles of opioid receptor subtype in the spinal antinociception of selective cyclooxygenase 2 inhibitor. Korean J Pain 23 236 PMID: 21217886
Passafaro et al (2011) Cholinergic Autoantibodies from Primary Sjögren's Syndrome Inhibit Mucin Production via Phospholipase C and Cyclooxygenase-2 In the Rat Submandibular Gland. Neuroscience 8 138 PMID: 22013477
Alsaqati et al (2013) Investigation of the functional expression of purine and pyrimidine receptors in porcine isolated pancreatic arteries. Purinergic Signal 10 241 PMID: 24310605
Wong et al (2009) Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 104 228 PMID: 19096033
Gonnermann et al (2015) Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity. Oncoimmunology 4 e988460 PMID: 25949900
Do you know of a great paper that uses DuP 697 from Tocris? Please let us know.
Reviews for DuP 697
There are currently no reviews for this product. Be the first to review DuP 697 and earn rewards!
Have you used DuP 697?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.